U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07175389) titled 'JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure' on Sept. 09.
Brief Summary: The goal of this clinical trial is to evaluate the safety and efficacy of JDB153 combined with Serplulimab in patients with pancreatic cancer after standard treatment failure.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Refractory Pancreatic Ductal Adenocarcinoma
Refractory Pancreatic Adenocarcinoma
Intervention:
DRUG: JDB153
JDB153 is administered orally at doses of 600 mg twice daily (1200 mg total daily dose) or 500 mg twice daily (1000 mg total daily dose) based on safety and tolerabili...